Register
Medicines reference
Product

Leventa

Levothyroxine · Intervet International B.V.

1 form: solution. No registration in force in Georgia.

Forms and doses0 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Solution · Dog Dog 0.01–0.04 ml/kg
For the specified levothyroxine oral solution, start at 20 micrograms/kg (0.2 mL/10 kg) once daily. Give at the same time each day, 2–3 hours before food. Titrate the maintenance dose within 10–40 micrograms/kg according to thyroid monitoring. Refrigerate and use within 6 months after opening.
· once daily
once daily Georgia No
Details: pack, label wording, sources, registration

Leventa, Solution

Levothyroxine sodium 1 mg/ml, oral solution for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Leventa

Levothyroxine sodium 1 mg/ml, oral solution for dogs
Assessed clinical scopeDog · Long-term thyroid-hormone replacement for confirmed hypothyroidism · By mouth
Care settingVeterinarian-directed lifelong replacement after diagnostic confirmation, with response-led dose titration and serial thyroid monitoring
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: No · Verified on 22 Oct 2026

An exact, evidence-supported canine liquid with fine dose adjustment; strong when diagnosis, food timing and T4-led titration are controlled.

Regulatory and scientific credibility9.0/10

Exact current GB and European authorisations identify the product, MA holder, species, strength, form and label. Georgia has no exact registration; US positives are different products.

Clinical efficacy8.5/10

Exact-product PK and clinical data support once-daily liquid replacement in hypothyroid dogs, with individual response-led adjustment.

Safety and tolerability7.5/10

Therapy is titratable and established, but uncorrected adrenal insufficiency, cardiac disease, over-replacement and drug interactions require diagnosis, staged dosing and monitoring.

Clinical practicality8.5/10

The 0.05 ml syringe supports fine adjustment; once-daily dosing is convenient. Refrigeration, food timing and the six-month broached life are material but manageable.

Full-course cost-effectiveness-

Current exact Georgian price/availability and a comparable treatment-period cost are not verified; cost is excluded.

Important safety and use flags

  • Confirm hypothyroidism with compatible clinical findings and appropriate thyroid testing; a low T4 during non-thyroidal illness or drug exposure is not sufficient by itself.
  • This rating is exact-product specific. Thyroxanil tablet and Leventa solution differ in formulation, bioavailability, starting regimen, food instruction, pack and monitoring; do not convert blindly between them.
  • Leventa is for dogs only. Give consistently 2–3 hours before food; concurrent food materially reduces/delays absorption. Use the supplied 0.05 ml syringe, refrigerate and discard six months after opening.
  • Clinical improvement and T4 response guide titration; recheck after starting or each dose change. Lifelong therapy should not continue on an unconfirmed diagnosis merely because nonspecific signs improve.
  • Do not use with uncorrected adrenal insufficiency. Thyroid replacement can increase metabolic and cardiac demand; stabilize concurrent disease and introduce cautiously where cardiovascular disease is present.
  • Over-replacement causes thyrotoxicosis: restlessness, tachycardia, panting, polydipsia/polyuria, weight loss, polyphagia and heat intolerance. Reduce/withhold and reassess dose and diagnosis if these appear.
  • Monitor clinical response and appropriately timed T4; consider TSH and routine laboratory/cardiovascular assessment when indicated. Sample timing must match the exact product’s label.
  • Phenobarbital, antacids, furosemide and other medicines can alter thyroid-hormone binding, absorption or metabolism. Review interacting drugs and interpret thyroid tests in that context.
  • The solution permits fine volume adjustment, but only after accurate weighing and response-led titration. Do not substitute a tablet dose-volume conversion without accounting for formulation-specific bioavailability.
  • Exact Thyroxanil and Leventa are authorised in GB/European jurisdictions but not registered in Georgia. US Thyro-Tabs is a distinct dog-only tablet and does not confer US approval on either exact product.
Assessment sources
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Levothyroxine1 mg/ml
Formulation Type
Solution
Administration route
By mouth
Manufacturer
Registration
Georgia No
EU Yes, veterinary
№ IE/V/0182/001
Verified on: 22 Oct 2026
UK Yes, veterinary
№ Vm 06376/5058
Verified on: 22 Oct 2026
US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Exact 30 ml refrigerated oral solution supplied with a 0.05 ml graduated syringe. Start and titrate only per the current label and clinical/T4 response; administer consistently 2–3 hours before food. Use within six months after opening.
DoseSpeciesWeightRouteFrequencySource
0.01–0.04 ml/kg
For the specified levothyroxine oral solution, start at 20 micrograms/kg (0.2 mL/10 kg) once daily. Give at the same time each day, 2–3 hours before food. Titrate the maintenance dose within 10–40 micrograms/kg according to thyroid monitoring. Refrigerate and use within 6 months after opening.
Dog Any weight By mouth once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Leventa 1 mg/ml Oral Solution for Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use levothyroxine in dogs with uncorrected hypoadrenocorticism. Stabilise glucocorticoid and mineralocorticoid replacement first, then start levothyroxine at 25% of the usual dose and increase by 25% every 2 weeks as needed.
    Sources: Product label
  • Critical
    Do not use levothyroxine in animals with hyperthyroidism or thyrotoxicosis.
  • Critical
    Known hypersensitivity to levothyroxine or any excipient is a contraindication.
  • Warning
    Levothyroxine can stress a poorly functioning heart and precipitate decompensation or congestive heart failure. In patients with cardiac disease, start at 25% of the usual dose and increase by 25% every 2 weeks until stable.
  • Caution
    Levothyroxine can alter insulin requirements in diabetic patients. Start cautiously, monitor glycaemic control, and adjust insulin as needed.
  • Caution
    Product information on levothyroxine use during pregnancy is inconsistent: some products permit it, while others have not established safety. If treatment is necessary, use the selected product’s guidance and monitor thyroid status regularly because dose requirements can change.
  • Caution
    Product information on levothyroxine use during lactation is inconsistent: some products permit it, while others have not established safety. Use the selected product’s guidance and monitor the patient when treatment is necessary.

Known Drug Interactions

  • Minor warning Levothyroxine + Calcium Carbonate
    Antacids containing aluminium, magnesium, or calcium, as well as ferrous sulfate and sucralfate, can reduce levothyroxine absorption.
    Recommendation: Separate levothyroxine from antacids, iron, or sucralfate by at least 2 hours.
  • Minor warning Levothyroxine + Ferrous sulfate
    Antacids containing aluminium, magnesium, or calcium, as well as ferrous sulfate and sucralfate, can reduce levothyroxine absorption.
    Recommendation: Separate levothyroxine from antacids, iron, or sucralfate by at least 2 hours.
  • Minor warning Levothyroxine + Insulin glargine
    Starting or changing levothyroxine supplementation in a diabetic dog receiving insulin can alter the insulin requirement.
    Recommendation: Monitor glycaemic control frequently when starting levothyroxine.
  • Minor warning Levothyroxine + Insulin human
    Starting or changing levothyroxine supplementation in a diabetic dog receiving insulin can alter the insulin requirement.
    Recommendation: Monitor glycaemic control frequently when starting levothyroxine.
  • Minor warning Sucralfate + Levothyroxine
    Antacids containing aluminium, magnesium, or calcium, as well as ferrous sulfate and sucralfate, can reduce levothyroxine absorption.
    Recommendation: Separate levothyroxine from antacids, iron, or sucralfate by at least 2 hours.
  • Minor warning Furosemide + Levothyroxine
    Several drugs, including barbiturates, antacids, anabolic steroids, diazepam, and furosemide, can alter thyroid-hormone binding or metabolism and may affect the response to levothyroxine.
    Recommendation: Recheck T4 and adjust the dose as needed.
  • Minor warning Levothyroxine + Magnesium Carbonate
    Antacids containing aluminium, magnesium, or calcium, as well as ferrous sulfate and sucralfate, can reduce levothyroxine absorption.
    Recommendation: Separate levothyroxine from antacids, iron, or sucralfate by at least 2 hours.
  • Minor warning Levothyroxine + Phenobarbital
    Several drugs, including barbiturates, antacids, anabolic steroids, diazepam, and furosemide, can alter thyroid-hormone binding or metabolism and may affect the response to levothyroxine.
    Recommendation: Recheck T4 and adjust the dose as needed.

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.